Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10F | NM | - | Nutlin 3a | MDM2 | MDM2 | 7486.066 | uM | 30.82790 | 51.28480 | -0.2762 | -0.9996 | 2.1580 | 0.1174 | 0.9652 | 1.0443 | |
MCF 10F | NM | - | Nutlin 3a | MDM2 | MDM2 | 7487.066 | uM | 1.54450 | 2.52030 | -0.0370 | -0.1622 | 0.5736 | 0.3237 | 0.9698 | 1.5845 | |
MCF 10F | NM | - | Olomoucine II | CDK1 | CDK | 12254.147 | uM | 8.6670 | 11.25160 | -0.7461 | -0.7463 | 3.4996 | 0.3007 | 0.9972 | 1.4316 | |
MCF 10F | NM | - | Omipalisib | PI3K | PI3K | 7486.087 | uM | 0.00232 | 0.00779 | -0.8112 | -0.6266 | 0.6698 | 1.0335 | 0.9769 | 1.1994 | |
MCF 10F | NM | - | Oxaliplatin | DNA cross-linker | DNA cross-linker | 9566.011 | uM | 9.96330 | 55.66130 | -0.8028 | -1.0000 | 0.6386 | 0.4382 | 0.9651 | 2.3358 | |
MCF 10F | NM | - | Oxamflatin | HDAC | HDAC | 12254.147 | uM | 3.72480 | 5.77440 | -0.8841 | -0.8888 | 2.3301 | 0.3318 | 0.9976 | 1.4316 | |
MCF 10F | NM | - | PD 98059 | MEK | MAPK | 12254.152 | uM | inf | inf | 0.9135 | 0.9135 | 0.0000 | 0.0088 | -0.0224 | 1.8382 | |
MCF 10F | NM | - | PD173074 | FGFR1/3 | RTK | 7486.1 | uM | 8.64950 | 10.98790 | -0.6368 | -0.6401 | 3.4444 | 0.2249 | 0.9969 | 1.0281 | |
MCF 10F | NM | - | PD184352 | MEK | MAPK | 12254.155 | uM | inf | inf | 0.9696 | 0.9696 | 0.0000 | 0.0271 | -0.1748 | 1.8150 | |
MCF 10F | NM | - | PD184352 | MEK | MAPK | 12254.155 | uM | inf | inf | 0.9696 | 0.9696 | 0.0000 | 0.0271 | -0.1748 | 1.8150 | |
MCF 10F | NM | - | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7486.095 | uM | inf | 0.06460 | 0.5367 | 0.5903 | 2.5181 | 0.3337 | 0.9222 | 0.9448 | |
MCF 10F | NM | - | Pertuzumab | 7487.102 | mg/ml | inf | 124.94960 | 0.6533 | -0.1750 | 0.2135 | 0.1284 | 0.7894 | 1.5273 | |||
MCF 10F | NM | - | PS-1145 | IKK | NFKB | 7486.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0198 | -0.3050 | 1.1517 | |
MCF 10F | NM | - | Purvalanol A | CDK1 | CDK | 7487.067 | uM | 15.83450 | 19.10550 | -0.3555 | -0.3584 | 2.8777 | 0.2502 | 0.9932 | 1.3523 | |
MCF 10F | NM | - | Ribavirin | 15393.211 | uM | inf | inf | 0.8354 | 0.8354 | 0.0000 | 0.0133 | 0.5287 | 1.6449 | |||
MCF 10F | NM | - | SB-3CT | MMP2/9 | MMP | 12254.144 | uM | inf | 90.76240 | 0.7601 | 0.5395 | 0.6974 | 0.0329 | 0.880 | 1.8842 | |
MCF 10F | NM | - | Selumetinib | MEK | MAPK | 12254.155 | uM | 3.47030 | 1.42990 | 0.2918 | 0.2685 | 0.8687 | 0.1974 | 0.9911 | 1.8150 | |
MCF 10F | NM | - | Sigma A6730 | AKT | AKT | 12254.165 | uM | 5.30860 | 13.62360 | -0.8736 | -1.0000 | 1.1657 | 0.3086 | 0.9783 | 1.6980 | |
MCF 10F | NM | - | Sirolimus | MTOR | MTOR | 7488.068 | uM | inf | 0.00504 | 0.4498 | 0.5302 | 1.0402 | 0.3713 | 0.9434 | 1.3560 | |
MCF 10F | NM | - | Sirolimus | MTOR | MTOR | 7487.068 | uM | 0.03924 | 0.00853 | 0.2145 | 0.2858 | 0.5554 | 0.5279 | 0.9462 | 1.5003 | |
MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 7487.084 | uM | 31.64230 | 39.28480 | -0.9804 | -0.9749 | 5.0000 | 0.4724 | 0.9984 | 1.3396 | |
MCF 10F | NM | - | Sunitinib | PDGFR/VEGFR/KIT/FLT3 | RTK | 7487.067 | uM | 3.76440 | 6.08440 | -0.9938 | -0.9215 | 2.1762 | 0.4657 | 0.9962 | 1.3523 | |
MCF 10F | NM | - | Taxol | TUBB | TUBB | 9566.002 | uM | 0.00946 | 0.00932 | -0.0125 | 0.0126 | 1.6921 | 0.6239 | 0.9970 | 2.0986 | |
MCF 10F | NM | - | TCS 2312 | CHK1 | CHK | 12254.152 | uM | 2.26720 | 3.19210 | -0.6299 | -0.6350 | 2.3960 | 0.2935 | 0.9981 | 1.8382 | |
MCF 10F | NM | - | TCS PIM-1 1 | Pim kinase | PIM | 12254.135 | uM | inf | 32.85480 | 0.5969 | 0.5482 | 1.5057 | 0.0433 | 0.9505 | 1.6637 |